Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu(Duke University), Ursula A. Matulonis(Dana-Farber Cancer Institute), Philippa Quy(Dana-Farber Cancer Institute), Jean Hurteau(University of Illinois Chicago), Gini F. Fleming(University of Chicago Medical Center), Ronald J. Buckanovich(Magee-Womens Research Institute), Sreenivasa Nattam(Fort Wayne Medical Institute), Eric P. Winer(University of Vermont), Mary K. Buss(University of Connecticut), S. Percy Ivy(National Cancer Institute), B.J. Rimel(Cedars-Sinai Medical Center), Jung Min Lee(Kyung Hee University), Hang Lee(Massachusetts General Hospital), Michael J. Birrer(University of Arkansas Medical Center), Weixiu Luo(Dana-Farber Cancer Institute), Christin Whalen(Dana-Farber Cancer Institute), Elise C. Kohn(National Cancer Institute), William T. Barry(Harvard University), Lisa Obermayer(Dana-Farber Cancer Institute)
Cited by 586
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k